These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17564580)

  • 1. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme.
    Searles A; Jefferys S; Doran E; Henry DA
    Med J Aust; 2007 Aug; 187(4):236-9. PubMed ID: 17564580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic drugs: international trends and policy developments in Australia.
    Lofgren H
    Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
    Clarke PM
    Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
    [No Abstract]   [Full Text] [Related]  

  • 12. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
    Faunce TA
    Med J Aust; 2007 Aug; 187(4):240-2. PubMed ID: 17564579
    [No Abstract]   [Full Text] [Related]  

  • 16. PBS reform - a missed opportunity?
    de Boer R
    Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some drugs more equal than others: pseudo-generics and commercial practice.
    Probyn AJ
    Aust Health Rev; 2004 Nov; 28(2):207-17. PubMed ID: 15527401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.